News Archive

Endometrial Cancer Trial: Clinical Phase Completed

Endometrial Cancer Trial: Clinical Phase Completed

There is hope that a new therapy will one day be available for women with endometrial cancer, following the completion of the clinical phase of an important Phase 3 study of Zoptrex (zoptarelin doxorubicin). Proceed to Press Release issued by Aeterna Zentaris, Inc.

Call to Screen Type 2 Diabetics for Pancreatic Cancer

Call to Screen Type 2 Diabetics for Pancreatic Cancer

November 21, 2016: Dr Lorraine Chantrill discusses Type 2 diabetes and pancreatic cancer. While no link between these two diseases has been established, Dr Chantrill says tumours can affect normal insulin production and a surprise diabetes diagnosis may sometimes be an early cancer warning.

Sports Broadcaster Takes On New Sporting Challenge

Sports Broadcaster Takes On New Sporting Challenge

October 20, 2016: Specialised Therapeutics Australia (STA) has a particular interest in pancreatic cancer and is committed to supporting efforts to advance understanding and improve clinical outcomes in this disease. Testimony to this commitment, we recently sponsored well-known television personality and sports broadcaster Tiffany Cherry to participate in the GI Cancer Institute’s ‘Gutsy Challenge’ - a seven day cycling challenge across Cambodia to raise awareness and vital funding for Australian research into GI cancers.

Shelli's Story: How Breast Cancer inspired 'Kit for Cancer'

Shelli's Story: How Breast Cancer inspired 'Kit for Cancer'

October 10, 2016: Two and a half years ago, Melbourne based high flyer Shelli Whitehurst was diagnosed with Stage 4 breast cancer. The devastating diagnosis inspired her to found a business that’s now helping other cancer patients around the world.

ICLUSIG™ to be PBS Listed November 1, 2015

ICLUSIG™ to be PBS Listed November 1, 2015

October, 2015: Specialised Therapeutics Australia (STA) is delighted to announce that ICLUSIG™ has received a confirmed listing date of 1 November 2015.

Updated Pancreatic Cancer Data Presented At International Cancer Conference

Updated Pancreatic Cancer Data Presented At International Cancer Conference

January, 2014: A leading breast cancer drug, ABRAXANE® (nanoparticle albumin-bound paclitaxel), has been shown to extend overall survival (OS) for patients with metastatic pancreatic cancer when used in combination with current standard of care, gemcitabine, with some patients surviving longer than three years.1

Melbourne Biopharmaceutical Company Named First Corporate Sponsor of International Medical Aid Organisation

Melbourne Biopharmaceutical Company Named First Corporate Sponsor of International Medical Aid Organisation

June, 2013: Melbourne biopharmaceutical company Specialised Therapeutics Australia has become the first corporate sponsor of an international charitable organisation which enables medical and surgical specialists to impart their expertise to colleagues in developing countries.

ABRAXANE Meets Primary Endpoint of Overall Survival Improvement in Phase III Advanced Pancreatic Cancer Study

ABRAXANE Meets Primary Endpoint of Overall Survival Improvement in Phase III Advanced Pancreatic Cancer Study

November, 2012: Specialised Therapeutics Australia (STA) is pleased to announce that the phase III, randomised, international study of ABRAXANE® (nanoparticle albumin-bound paclitaxel) in combination with gemcitabine in treatment-naïve patients with advanced pancreatic cancer met its primary endpoint of overall survival.

New Drug To Fight Hospital Superbug Infection

New Drug To Fight Hospital Superbug Infection

June, 2012: A new therapy to treat a common hospital superbug* infection Clostridium difficile, will soon be available to Australian & New Zealand patients.

Royal Melbourne Hospital: First Public Hospital in Australia to Adopt New Technology for Brain Tumour Surgery

Royal Melbourne Hospital: First Public Hospital in Australia to Adopt New Technology for Brain Tumour Surgery

May, 2012: Patients with an aggressive form of brain tumour, glioblastoma multiforme (GBM), have been given access to a new brain tumour visualisation drug, Gliolan® (5-aminolevulinic acid), at The Royal Melbourne Hospital.

First Australian Patients Treated With New Brain Tumour Drug - Gliolan®

First Australian Patients Treated With New Brain Tumour Drug - Gliolan®

September, 2011: Two Australian patients have undergone surgery with the aid of a new drug which assists neurosurgeons to visualise and remove high grade gliomas - brain tumours which typically have a poor prognosis.

Specialised Therapeutics’ Compassionate Program has provided cancer patients access to over $1m of cancer drug, ABRAXANE® since TGA approval

Specialised Therapeutics’ Compassionate Program has provided cancer patients access to over $1m of cancer drug, ABRAXANE® since TGA approval

August, 2010: Hundreds of cancer patients around Australia have had free and subsidised access to a world leading cancer drug, under a compassionate program administered by the family-owned bio-pharmaceutical company which markets the treatment in Australia.

ABRAXANE® in Focus at International Conference

ABRAXANE® in Focus at International Conference

May, 2010: World leading advanced breast cancer drug ABRAXANE® (nanoparticle albumin-bound paclitaxel) will be in focus at a leading international medical conference in Chicago next week.

Rare Cancers Australia - A focus on less common cancers

Rare Cancers Australia - A focus on less common cancers

Rare Cancers Australia - A focus on less common cancers